Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P35557

UPID:
HXK4_HUMAN

ALTERNATIVE NAMES:
Glucokinase; Hexokinase type IV; Hexokinase-D

ALTERNATIVE UPACC:
P35557; A4D2J2; A4D2J3; Q05810

BACKGROUND:
Hexokinase-4, known alternatively as Glucokinase or Hexokinase-D, is essential for glucose metabolism, facilitating the conversion of glucose to glucose 6-phosphate. This enzyme's unique low affinity for glucose allows it to function effectively across physiological glucose concentrations, serving as a critical glucose sensor in pancreatic beta cells and influencing insulin secretion and hepatic glucose processing.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Hexokinase-4 could open doors to potential therapeutic strategies. Its direct association with various forms of diabetes, including Maturity-onset diabetes of the young 2 and Type 2 diabetes mellitus, highlights its significance in metabolic disease pathways and the development of targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.